J Am Pharm Assoc (2003). 2022 Jul-Aug;62(4):1313-1320.e6. doi: 10.1016/j.japh.2022.02.015. Epub 2022 Feb 25.
Pharmacists can play an important role in pain management.
OBJECTIVE(S): This review aims to summarize the effects of any type of pharmacist intervention, whether led by a pharmacist or in a supportive role, on pain intensity over time in individuals with pain of any etiology.
Three electronic databases (MEDLINE, Embase, and Cochrane Central Register of Controlled Trials) were searched from inception to the end of May 2021 to identify randomized controlled trials (RCTs) that reported the effect of pharmacist interventions on pain intensity. Two reviewers independently extracted data and evaluated study quality. The analyses used a random-effects models and the Grading of Recommendations, Assessment, Development and Evaluation to rate the certainty of the evidence. The primary outcome was reduction in pain intensity and presented as standardized mean differences (SMD).
Twelve RCTs including 1710 participants were included. Pooled estimate of 12 studies demonstrated a statistically significant reduction in pain intensity compared with control (SMD -0.22 [95% CI -0.31 to -0.12], I = 0%, low certainty). The intervention was more effective when a pharmacist delivered a combination of services comprising educational interventions, medication review, and pharmaceutical care services (SMD -0.24 [95% CI -0.35 to -0.13], I = 0%, moderate certainty). For educational interventions alone, no statistically significant difference was observed (SMD -0.15 [95% CI -0.45 to 0.15], I = 47.6%, low certainty). Pharmacist intervention was also effective in reducing pain intensity for patients with cancer-related pain (SMD -0.76 [95% CI -1.17 to -0.36], I = 0%, moderate certainty).
There is some promising evidence to suggest that multicomponent pharmacist interventions including medication review or any other pharmaceutical care services, rather than merely educational interventions, are beneficial in reducing pain intensity, particularly in patients with chronic pain. High-quality RCTs are required to confirm the clinical significance of this findings before advocating for its widespread implication in clinical practice.
药剂师可以在疼痛管理中发挥重要作用。
本综述旨在总结任何类型的药剂师干预措施(无论是由药剂师主导还是提供支持)对各种病因所致疼痛患者随时间推移的疼痛强度的影响。
从建库到 2021 年 5 月底,我们在三个电子数据库(MEDLINE、Embase 和 Cochrane 对照试验中心注册库)中检索了随机对照试验(RCT),以确定报告药师干预对疼痛强度影响的研究。两位审查员独立提取数据并评估研究质量。分析采用随机效应模型和 Grading of Recommendations, Assessment, Development and Evaluation 来评估证据的确定性。主要结局是疼痛强度的降低,表现为标准化均数差(SMD)。
纳入 12 项 RCT,共 1710 名参与者。12 项研究的汇总估计表明,与对照组相比,疼痛强度有统计学显著降低(SMD-0.22[95%CI-0.31 至-0.12],I²=0%,低确定性)。当药剂师提供包括教育干预、药物审查和药物治疗服务在内的综合服务时,干预效果更为显著(SMD-0.24[95%CI-0.35 至-0.13],I²=0%,中等确定性)。仅进行教育干预时,未观察到统计学显著差异(SMD-0.15[95%CI-0.45 至 0.15],I²=47.6%,低确定性)。药师干预对癌症相关疼痛患者的疼痛强度也有降低作用(SMD-0.76[95%CI-1.17 至-0.36],I²=0%,中等确定性)。
有一些有希望的证据表明,包括药物审查或任何其他药物治疗服务在内的多组分药剂师干预措施,而不仅仅是教育干预措施,有利于降低疼痛强度,特别是对慢性疼痛患者。需要高质量的 RCT 来确认这些发现的临床意义,然后才能提倡将其广泛应用于临床实践。